Technology | Vascular Closure Devices | April 10, 2018

Vascade Vascular Closure System Approved for Femoral Vein Closure

Cardiva Medical’s device now indicated for both arterial and venous vascular closure

Vascade Vascular Closure System Approved for Femoral Vein Closure

April 10, 2018 – Cardiva Medical announced the company received U.S. Food and Drug Administration (FDA) approval for an expanded indication of the Vascade Vascular Closure System. Already approved for use in arterial closure, Vascade is now FDA-approved for use in 5-7F femoral venous closures as well. This expansion creates an opportunity to better treat patients undergoing interventional cardiac catheterization procedures, while also greatly increasing the available market for the device.

The Vascade System consists of a thrombogenic bioabsorbable collagen patch and proprietary collapsible disc technology that is clinically proven to safely and effectively achieve hemostasis while minimizing complications, according to the company. Unlike manual compression, which is the current standard for femoral access site closure, Vascade does not require prolonged, heavy pressure and extended bed rest to ensure hemostasis.

“Vascade has performed exceptionally well for our current patients, and this new indication will empower many physicians to use Vascade for vein closure," said Joseph De Gregorio, M.D., chief of invasive cardiology at Englewood Hospital and Medical Center in New Jersey. "Successful vessel closure, and enabling a patient to walk as soon as possible after their procedure, are critical factors for recovery from interventional procedures. The ease of use of the Vascade system and its compelling clinical data will make it an attractive new option for closure following vein procedures.”  

Results of a study evaluating Vascade for venous closures were published in Vascular Disease Management. The authors noted that the “device achieved complete hemostasis without any recorded vascular complications, and was effective in providing earlier ambulation and discharge compared with our standard protocol for manual compression.” In the same article, the authors emphasize that access site complications remain the most common complication from cardiac catheterization procedures that require venous access.[1]

Vascade is commercially available in the United States, where it has been approved by the FDA (2013), and has received CE mark (2012).

For more information: www.cardivamedical.com

 

Reference:

1. Nagabandi, A. et al. Use of Vascade Vascular Closure System for Venous Hemostasis.  Vascular Disease Management; 2017;14(8):E171-E173.

Related Content

TCT cancels in-person meeting and goes virtual due to COVID-19
News | Cath Lab | May 27, 2020
May 27, 2020 — To ensure the health and safety of all attendees due to the ongoing COVID-19 (SARS-CoV-2) pandemic, th
Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, or nil per os (NPO), as there are no current standardized fasting protocols, but the CHOWNOW study found patients do not need to fast and will have similar outcomes. #SCAI2020
Feature | Cath Lab | May 18, 2020
May 18, 2020 – Patients undergoing cardiac catheterization are traditionally instructed to follow nothing by mouth, o
htisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiography and Interventions (SCAI) and chief, Division of Cardiovascular Medicine at UC San Diego Medical Center,
Podcast | Cath Lab | May 13, 2020
This podcast is an interview with Ehtisham Mahmud, M.D., FSCAI, president of the Society for Cardiovascular Angiograp
Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...